While the role of obesity in gastroesophageal reflux disease (GERD) and the role of GERD in Barrett’s esophagus (BE) are independently well established, there is

Prateek Sharma, MD, FASGE, reviewing Krishnamoorthi R, et al. Gastrointest Endosc 2020 Jan. The risk of progression in Barrett’s esophagus (BE) with low-grade dysplasia has

Multimodal therapy for early Barrett’s neoplasias, has become established as the standard therapy and is set out in national and international guidelines. These dysplastic lesions

Almost everybody prescribes at least low-dose PPI to their Barrett patients even if they complete asymptomatic – is this warranted?

The Prague classification was presented by an international research group in 2006 (1) and has since been regarded as the standard for measuring the length

Gastroesophageal reflux disease with endoscopically identifiable lesions (erosions, stricture, Barrett’s esophagus) is defined as erosive gastroesophageal reflux disease (GERD). Fewer than 50% of patients with

A 46-year-old patient with short-segment Barrett’s esophagus that had been receiving monitoring since 2009, now presenting with a mucosal adenocarcinoma.

Low-grade dysplasia (low-grade intraepithelial neoplasia, LGIN) is difficult to distinguish from inflammation histopathologically. The interobserver variance rates usually show kappa values below 0.4, representing a